Targeting heat shock proteins in metastatic castration-resistant prostate cancer

Nature Reviews Urology

Volumn 12, Issue 1, 2015, Pages 26-36

  Azad, Arun A ^a   Zoubeidi, Amina ^b   Gleave, Martin E ^b   Chi, Kim N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; TUMOR MARKER;

CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL PROTECTION; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; ANTAGONISTS AND INHIBITORS; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; HEAT-SHOCK PROTEINS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84924908864     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.320     Document Type: Review

References (54)

1. Calderwood, S. K. & Ciocca, D. R. Heat shock proteins: stress proteins with Janus-like properties in cancer. Int. J. Hyperthermia 24, 31-39 (2008)
2. Zoubeidi, A. & Gleave, M. Small heat shock proteins in cancer therapy and prognosis. Int. J. Biochem. Cell Biol. 44, 1646-1656 (2012)
3. Ischia, J. & So, A. I. The role of heat shock proteins in bladder cancer. Nat. Rev. Urol. 10, 386-395 (2013)
4. Ischia, J., Saad, F. & Gleave, M. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Curr. Opin. Urol. 23, 194-200 (2013)
5. Akerfelt, M., Morimoto, R. I. & Sistonen, L. Heat shock factors: integrators of cell stress, development and lifespan. Nat. Rev. Mol. Cell Biol. 11, 545-555 (2010)
6. Pirkkala, L., Nykänen, P. & Sistonen, L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J. 15, 1118-1131 (2001)
7. Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761-772 (2005)
8. Jego, G., Hazoumé, A., Seigneuric, R. & Garrido, C. Targeting heat shock proteins in cancer. Cancer Lett. 332, 275-285 (2013)
9. Cano, L. Q., Lavery, D. N. & Bevan, C. L. Mini-review: Foldosome regulation of androgen receptor action in prostate cancer. Mol. Cell. Endocrinol. 369, 52-62 (2013)
10. Fang, Y., Fliss, A. E., Robins, D. M. & Caplan, A. J. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J. Biol. Chem. 271, 28697-28702 (1996)
11. Zoubeidi, A. et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 67, 10455-10465 (2007)
12. Ryan, C. J. & Tindall, D. J. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J. Clin. Oncol. 29, 3651-3658 (2011)
13. Powers, M. V. & Workman, P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr. Relat. Cancer 13 (Suppl. 1), S125-S135 (2006)
14. Taipale, M., Jarosz, D. F. & Lindquist, S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11, 515-528 (2010)
15. Mollapour, M. & Neckers, L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim. Biophys. Acta 1823, 648-655 (2012)
16. Ferraldeschi, R. et al. In vitro and in vivo antitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models [abstract 2433]. Cancer Res. http://dx.doi.org/10.1158/1538-7445.AM2013-2433
17. Eskew, J. D. et al. Development and characterization of a novel Cterminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 11, 468 (2011)
18. He, S. et al. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int. J. Oncol. 42, 35-43 (2013)
19. Centenera, M. M. et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin. Cancer Res. 18, 3562-3570 (2012)
20. Plescia, J. et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7, 457-468 (2005)
21. Solit, D. B. et al. 17 Allylamino 17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 8, 986-993 (2002)
22. Matthews, S. B. et al. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 70, 27-36 (2010)
23. Lamoureux, F. et al. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin. Cancer Res. 17, 2301-2313 (2011)
24. Eccles, S. A. et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 68, 2850-2860 (2008)
25. Hance, M. W. et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J. Biol. Chem. 287, 37732-37744 (2012)
26. Teng, Y., Ngoka, L., Mei, Y., Lesoon, L. & Cowell, J. K. HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein. J. Biol. Chem. 287, 10051-10059 (2012)
27. Alqawi, O., Moghaddas, M. & Singh, G. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer Prostatic Dis. 9, 126-135 (2006)
28. Mabjeesh, N. J. et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62, 2478-2482 (2002)
29. Vanaja, D. K., Mitchell, S. H., Toft, D. O. & Young, C. Y. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7, 55-64 (2002)
30. Saporita, A. J., Ai, J. & Wang, Z. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67, 509-520 (2007)
31. O'Malley, K. J. et al. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate 72, 1117-1123 (2012)
32. Chandarlapaty, S. et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 14, 240-248 (2008)
33. Heath, E. I. et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14, 7940-7946 (2008)
34. Pacey, S. et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 17, 1561-1570 (2011)
35. Oh, W. K. et al. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 78, 626-630 (2011)
36. Heath, E. I. et al. Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel-based chemotherapy: Results of a Prostate Cancer Clinical Trials Consortium (PCCTC) study [abstract 5085]. J. Clin. Oncol. 31 (Suppl.) (2013)
37. Rajan, A. et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin. Cancer Res. 17, 6831-6839 (2011)
38. Mattos-Arruda, L. D. et al. Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies [abstract 2561]. J. Clin. Oncol. 31 (Suppl.) (2013)
39. Kang, B. H. et al. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin. Cancer Res. 16, 4779-4788 (2010)
40. Lamoureux, F. et al. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Eur. Urol. 66, 145-155 (2014)
41. Lamoureux, F. et al. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res. 71, 5838-5849 (2011)
42. Ciocca, D. R., Arrigo, A. P. & Calderwood, S. K. Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch. Toxicol. 87, 19-48 (2013)
43. Shatkina, L. et al. The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor. Mol. Cell. Biol. 23, 7189-7197 (2003)
44. Ren, A., Yan, G., You, B. & Sun, J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res. 68, 2266-2274 (2008)
45. Gibbons, N. B., Watson, R. W., Coffey, R. N., Brady, H. P. & Fitzpatrick, J. M. Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 45, 58-65 (2000)
46. Roigas, J., Wallen, E. S., Loening, S. A. & Moseley, P. L. Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells. Prostate 34, 195-202 (1998)
47. Gabai, V. L., Budagova, K. R. & Sherman, M. Y. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 24, 3328-3338 (2005)
48. Koya, K. et al. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res. 56, 538-543 (1996)
49. Britten, C. D. et al. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin. Cancer Res. 6, 42-49 (2000)
50. Parcellier, A. et al. Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid. Redox Signal. 7, 404-413 (2005)
51. Rocchi, P. et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 65, 11083-11093 (2005)
52. Andrieu, C. et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 29, 1883-1896 (2010)
53. Baylot, V. et al. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol. Ther. 20, 2244-2256 (2012)
54. Zoubeidi, A. et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res. 70, 2307-2317 (2010).